A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration

NCT ID: NCT03814291

Last Updated: 2025-04-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 31 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2019-04-15
• Study Completion Date: 2020-04-10

Brief Summary

This study is designed for single-center, open-label, dose escalation phase I trial to evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients with wet AMD.

Conditions

Neovascular Age-related Macular Degeneration

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

cohort 1 IBI302 treated with first dose level of IBI302

Group Type: EXPERIMENTAL

IBI302

Intervention Type: DRUG

0.05mg/eye;Intraocular injection

cohort 2 IBI302 treated with second dose level of IBI302

Group Type: EXPERIMENTAL

IBI302

Intervention Type: DRUG

0.15mg/eye;Intraocular injection

cohort 3 IBI302 treated with third dose level of IBI302

Group Type: EXPERIMENTAL

IBI302

Intervention Type: DRUG

0.5mg/eye;Intraocular injection

cohort 4 IBI302 treated with fourth dose level of IBI302

Group Type: EXPERIMENTAL

IBI302

Intervention Type: DRUG

1mg/eye;Intraocular injection

cohort 5 IBI302 treated with fifth dose level of IBI302

Group Type: EXPERIMENTAL

IBI302

Intervention Type: DRUG

2mg/eye;Intraocular injection

cohort 6 IBI302 treated with sixth dose level of IBI302

Group Type: EXPERIMENTAL

IBI302

Intervention Type: DRUG

4mg/eye;Intraocular injection

Interventions

IBI302

0.05mg/eye;Intraocular injection

Intervention Type: DRUG

IBI302

0.15mg/eye;Intraocular injection

Intervention Type: DRUG

IBI302

0.5mg/eye;Intraocular injection

Intervention Type: DRUG

IBI302

1mg/eye;Intraocular injection

Intervention Type: DRUG

IBI302

2mg/eye;Intraocular injection

Intervention Type: DRUG

IBI302

4mg/eye;Intraocular injection

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female patient ≥ 50 yrs. of age.

2. Active subfoveal CNV secondary to wet AMD, with lesion size ≤ 12 optic discs in the study eye.

3. BCVA score of 10-73 letters using ETDRS charts (in 4 meters) in the study eye.

4. Central macular sub-field thickness according to OCT of at least 250 micron.

5. Clear stereoscopic fundus photography is obtained while the lens or other media is clear.

6. Female subjects of childbearing age or male subjects with childbearing age female partner agree to take effective contraceptive measures from the screening period to 3 months after the end of treatment.

7. Willing and able to sign informed consent form and comply with visit and study procedures per protocol.

Exclusion Criteria

1. Presence of other causes of CNV other than wet AMD in the study eye.

2. Presence of active diabetic retinopathy in the study eye.

3. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥30mmHg despite the standardized treatment).

4. Prior retinal detachment in the study eye.

5. Prior any treatment of following in the study eye:

1. Anti-VEGF therapy within 6 months prior to screening;

2. Anti-complement therapy;

3. Laser photocoagulation;

4. Photodynamic therapy;

5. Transpupillary thermotherapy

6. Intraocular surgery;

7. Intraocular or periocular glucocorticoid injection therapy within 6 months prior to enrollment;

6. Presence of any non-AMD disease that may affect visual acuity in the study eye

7. Prior anti-VEGF therapy within 1 month before study drug administration or plan of above anti-VEGF therapy in the non-study eye during the whole study.

8. Oral steroid drugs within 1 month before study drug administration.

9. Presence of active intraocular or periocular inflammation or infection.

10. Diabetic patients have any of the following conditions:

1. Microvascular and macrovascular complications;

2. HbA1c>7.5% when screening;

3. Receiving more than two oral hypoglycemic agents;

4. Receiving insulin or GLP-1 receptor agonist;

11. Hypertension (defined as systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg despite standard treatment);

12. Presence of any following laboratory abnormality:

1. PLT<100×109/L, INR≥1.5ULN, APTT≥ 10 seconds more than ULN;

2. ALT or AST >2ULN;

3. Cr or Ur>1.5ULN;

13. Large or medium surgery, or unhealed surgical incisions, ulcers or fractures within 1 month before study drug administration.

• Minimum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shanghai General Hospital

Shanghai, Shanghai Municipality, China

Countries

China

References

Yang S, Li T, Jia H, Gao M, Li Y, Wan X, Huang Z, Li M, Zhai Y, Li X, Yang X, Wang T, Liang J, Gu Q, Luo X, Qian L, Lu S, Liu J, Song Y, Wang F, Sun X, Yu D. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022 Jun;14(647):eabj2177. doi: 10.1126/scitranslmed.abj2177. Epub 2022 Jun 1.

Reference Type: DERIVED

PMID: 35648811 (View on PubMed)

Other Identifiers

CIBI302A101

Identifier Type: -

Identifier Source: org_study_id